DOCSLIB.ORG

Official Journal ISSN 0378-6978 L97 of the European Communities Volume 45

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Official Journal ISSN 0378-6978 L97 of the European Communities Volume 45 Official Journal ISSN 0378-6978 L97 of the European Communities Volume 45 13 April 2002 English edition Legislation Contents I Acts whose publication is obligatory ★ Commission regulation (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff ........................................ 1 Price: 22 EUR Acts whose titles are printed in light type are those relating to day-to-day management of agricultural matters, and are generally valid for a limited period. EN The titles of all other acts are printed in bold type and preceded by an asterisk. 13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods. dance with the opinion of the Customs Code Committee, (2) Following the amendments to the nomenclature annexed to the International Convention on the Harmonised Commod- HAS ADOPTED THIS REGULATION: ity Description and Coding System pursuant to the recom- mendation of 25 June 1999 of the Customs Cooperation Council, note 8 to Chapter 29 was inserted and the word- Article 1 ing of heading 2937 of the Combined Nomenclature was amended by Commission Regulation (EC) No 2031/2001 (3), with effect from 1 January 2002. Annex 3 to Section II of Part Three of Annex I to Regulation (EEC) No 2658/87 is hereby replaced by the Annex to this Regulation. (3) As a result of the new note 8 to Chapter 29 and the new wording of heading 2937, it is necessary to update Annex Article 2 3 (list of international non-proprietary names (INNs), pro- vided for pharmaceutical substances by the World Health This Regulation shall enter into force on the 20th day following Organisation, which are free of duty) of the Combined that of its publication in the Official Journal of the European Com- munities. (1) OJ L 256, 7.9.1987, p. 1. (2) OJ L 329, 14.12.2001, p. 4. (3) OJ L 279, 23.10.2001, p. 1. It shall apply from 1 January 2002. L 97/2 EN Official Journal of the European Communities 13.4.2002 This Regulation shall be binding in its entirety and directly applicable in all Member States. Done at Brussels, 20 March 2002. For the Commission Frederik BOLKESTEIN Member of the Commission 13.4.2002 EN Official Journal of the European Communities L 97/3 ANNEXES 13.4.2002 EN Official Journal of the European Communities L 97/5 ANNEX 3 LIST OF INTERNATIONAL NON-PROPRIETARY NAMES (INNS), PROVIDED FOR PHARMACEUTICAL SUBSTANCES BY THE WORLD HEALTH ORGANIZATION, WHICH ARE FREE OF DUTY CN Code CAS RN Name 2818 30 00 1330-44-5 algeldrate 2833 22 00 61115-28-4 alusulf 2842 10 00 71205-22-6 almasilate 12408-47-8 simaldrate 2842 90 90 60239-66-9 almadrate sulfate 66827-12-1 almagate 0-00-0 almagodrate 41342-54-5 carbaldrate 12304-65-3 hydrotalcite 74978-16-8 magaldrate 2843 30 00 34031-32-8 auranofin 16925-51-2 aurothioglycanide 12244-57-4 sodium aurothiomalate 10210-36-3 sodium aurotiosulfate 2843 90 90 41575-94-4 carboplatin 15663-27-1 cisplatin 96392-96-0 dexormaplatin 111523-41-2 enloplatin 62928-11-4 iproplatin 135558-11-1 lobaplatin 103775-75-3 miboplatin 95734-82-0 nedaplatin 62816-98-2 ormaplatin 61825-94-3 oxaliplatin 110172-45-7 sebriplatin 74790-08-2 spiroplatin 111490-36-9 zeniplatin 2844 40 20 14932-42-4 xenon (133 Xe) 2844 40 30 15690-63-8 cesium (131 Cs) chloride 10375-56-1 chlormerodrin (197 Hg) 13115-03-2 cyanocobalamin (57 Co) 18195-32-9 cyanocobalamin (58 Co) 13422-53-2 cyanocobalamin (60 Co) 8016-07-7 ethiodized oil (131 I) 54063-42-2 ferric (59 Fe) citrate injection 0-00-0 fibrinogen (125 I) 105851-17-0 fludeoxyglucose (18 F) 92812-82-3 fluorodopa (18 F) 41183-64-6 gallium (67 Ga) citrate 77679-27-7 iobenguane (131 I) 74855-17-7 iocanlidic acid (123 I) 9048-49-1 iodinated (125 I) human serum albumin 9048-49-1 iodinated (131 I) human serum albumin 54510-20-2 iodocetylic acid (123 I) 42220-21-3 iodocholesterol (131 I) 75917-92-9 iofetamine (123 I) 155798-07-5 ioflupane (123 I) 113716-48-6 iolopride (123 I) 127396-36-5 iomazenil (123 I) 17033-82-8 iometin (125 I) 17033-83-9 iometin (131 I) 136794-86-0 iometopane (123 I) 54182-63-7 macrosalb (131 I) 54277-47-3 macrosalb (99m Tc) 5579-94-2 merisoprol (197 Hg) 94153-50-1 mespiperone (11 C) 15251-14-6 rose bengal (131 I) sodium 154427-83-5 samarium (153 Sm) lexidronam 1187-56-0 selenomethionine (75 Se) 10039-53-9 sodium chromate (51 Cr) L 97/6 EN Official Journal of the European Communities 13.4.2002 CN Code CAS RN Name 2844 40 30 (cont’d) 24359-64-6 sodium iodide (125 I) 7790-26-3 sodium iodide (131 I) 881-17-4 sodium iodohippurate (131 I) 17692-74-9 sodium iotalamate (125 I) 15845-98-4 sodium iotalamate (131 I) 8027-28-9 sodium phosphate (32 P) 178959-14-3 technetium (99m Tc) apcitide 121281-41-2 technetium (99m Tc) bicisate 142481-95-6 technetium (99m Tc) furifosmin 165942-79-0 technetium (99m Tc) nofetumomab merpentan 157476-76-1 technetium (99m Tc) pintumomab 109581-73-9 technetium (99m Tc) sestamibi 106417-28-1 technetium (99m Tc) siboroxime 104716-22-5 technetium (99m Tc) teboroxime 54182-60-4 tolpovidone (131 I) 2844 40 80 10043-49-9 gold (198 Au), colloidal 2845 90 10 35523-45-6 fludalanine 122431-96-3 zilascorb (2 H) 2845 90 90 103831-41-0 sodium borocaptate (10 B) 2846 90 00 113662-23-0 gadobenic acid 138071-82-6 gadobutrol 131410-48-5 gadodiamide 117827-80-2 gadopenamide 80529-93-7 gadopentetic acid 72573-82-1 gadoteric acid 120066-54-8 gadoteridol 131069-91-5 gadoversetamide 135326-11-3 gadoxetic acid 138721-73-0 sprodiamide 2902 19 99 75-19-4 cyclopropane 2902 90 80 75078-91-0 temarotene 2903 44 10 76-14-2 cryofluorane 2903 47 00 423-55-2 perflubron 2903 49 30 124-72-1 teflurane 2903 49 80 151-67-7 halothane 2903 59 90 1715-40-8 bromociclen 306-94-5 perflunafene 2903 62 00 50-29-3 clofenotane 2903 69 90 479-68-5 broparestrol 34106-48-4 feniodium chloride 56917-29-4 fluretofen 53-19-0 mitotane 29041000 99287-30-6 egualen 5560-69-0 ethyl dibunate 14992-59-7 sodium dibunate 6223-35-4 sodium gualenate 29049020 124-88-9 dimethiodal sodium 126-31-8 methiodal sodium 2905 29 90 77-75-8 methylpentynol 2905 39 80 55-98-1 busulfan 35449-36-6 gemcadiol 64218-02-6 plaunotol 2905 49 90 7518-35-6 mannosulfan 299-75-2 treosulfan 13.4.2002 EN Official Journal of the European Communities L 97/7 CN Code CAS RN Name 2905 51 00 113-18-8 ethchlorvynol 2905 59 10 57-15-8 chlorobutanol 24403-04-1 debropol 2905 59 99 52-51-7 bronopol 2209-86-1 loprodiol 488-41-5 mitobronitol 10318-26-0 mitolactol 2906 11 00 15356-70-4 racementhol 2906 19 00 19793-20-5 bolandiol 112828-00-9 calcipotriol 29474-12-2 cimepanol 67-96-9 dihydrotachysterol 23089-26-1 levomenol 131918-61-1 paricalcitol 134404-52-7 seocalcitol 57333-96-7 tacalcitol 2906 29 00 104561-36-6 doretinel 583-03-9 fenipentol 15687-18-0 fenpentadiol 56430-99-0 flumecinol 13980-94-4 metaglycodol 79-93-6 phenaglycodol 14088-71-2 proclonol 29071900 1300-94-3 amylmetacresol 5591-47-9 cyclomenol 2078-54-8 propofol 13741-18-9 xibornol 29072900 85-95-0 benzestrol 84-17-3 dienestrol 56-53-1 diethylstilbestrol 10457-66-6 geroquinol 5635-50-7 hexestrol 27686-84-6 masoprocol 130-73-4 methestrol 2908 10 00 6915-57-7 bibrocathol 15686-33-6 biclotymol 34633-34-6 bifluranol 59-50-7 chlorocresol 88-04-0 chloroxylenol 10572-34-6 cicliomenol 37693-01-9 clofoctol 145-94-8 clorindanol 120-32-1 clorofene 97-23-4 dichlorophen 133-53-9 dichloroxylenol 127035-60-3 enofelast 70-30-4 hexachlorophene 65634-39-1 pentafluranol 64396-09-4 terfluranol 2908 20 00 20123-80-2 calcium dobesilate 78480-14-5 dicresulene 4444-23-9 persilic acid 57775-26-5 sultosilic acid 2908 90 00 10331-57-4 niclofolan 39224-48-1 nitroclofene 2909 19 00 57041-67-5 desflurane 13838-16-9 enflurane 333-36-8 flurotyl 406-90-6 fluroxene 26675-46-7 isoflurane 76-38-0 methoxyflurane 679-90-3 roflurane 28523-86-6 sevoflurane L 97/8 EN Official Journal of the European Communities 13.4.2002 CN Code CAS RN Name 2909 20 00 56689-41-9 aliflurane 2909 30 90 569-57-3 chlorotrianisene 55837-16-6 entsufon 80844-07-1 etofenprox 777-11-7 haloprogin 2909 49 19 544-62-7 batilol 2216-77-5
Load more

Recommended publications
  • Clinical Study Is Nonmicronized Diosmin 600Mg As Effective As
    Hindawi International Journal of Vascular Medicine Volume 2020, Article ID 4237204, 9 pages https://doi.org/10.1155/2020/4237204 Clinical Study Is Nonmicronized Diosmin 600mg as Effective as Micronized Diosmin 900mg plus Hesperidin 100mg on Chronic Venous Disease Symptoms? Results of a Noninferiority Study Marcio Steinbruch,1 Carlos Nunes,2 Romualdo Gama,3 Renato Kaufman,4 Gustavo Gama,5 Mendel Suchmacher Neto,6 Rafael Nigri,7 Natasha Cytrynbaum,8 Lisa Brauer Oliveira,9 Isabelle Bertaina,10 François Verrière,10 and Mauro Geller 3,6,9 1Hospital Albert Einstein (São Paulo-Brasil), R. Mauricio F Klabin 357/17, Vila Mariana, SP, Brazil 04120-020 2Instituto de Pós-Graduação Médica Carlos Chagas-Fundação Educacional Serra dos Órgãos-UNIFESO (Rio de Janeiro/Teresópolis- Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 3Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 4Faculdade de Ciências Médicas, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), Av. N. Sra. De Copacapana, 664/206, Rio de Janeiro, RJ, Brazil 22050-903 5Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Rua Prefeito Sebastião Teixeira 400/504-1, Rio de Janeiro, RJ, Brazil 25953-200 6Instituto de Pós-Graduação Médica Carlos Chagas (Rio de Janeiro-Brazil), R. General Canabarro 68/902, Rio de Janeiro, RJ, Brazil 20271-200 7Department of Medicine, Rutgers New Jersey Medical School-USA, 185 S Orange Ave., Newark, NJ 07103, USA 8Hospital Universitário Pedro Ernesto, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), R. Hilário de Gouveia, 87/801, Rio de Janeiro, RJ, Brazil 22040-020 9Universidade Federal do Rio de Janeiro (UFRJ) (Rio de Janeiro-Brazil), Av.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • IIIHIIIUSOO5304377A Unitedo States Patent 19 (11) Patent Number: 5,304,377 Yamada Et Al
    IIIHIIIUSOO5304377A UnitedO States Patent 19 (11) Patent Number: 5,304,377 Yamada et al. (45) Date of Patent: Apr. 19, 1994 54 PROLONGED RELEASE PREPARATION 4,954,298 9/1990 Yamamoto et al. ................. 264/4.6 AND POLYMERS THEREOF 4,962,091 10/1990 Eppstein et al. ........................ 514/2 75) Inventors: Minoru Yamada; Seiko Ishiguro, both 5,061,492 10/1991 Okada et al. ........................ 424/423 Otokuni, all of Japan 0052510 11/1981 European Pat. Off. 73) Assignee: Sherical4. industries, Ltd., O256726O190833 7/19871/1986 European Pat. Off. a, Japan 0263490 10/1987 European Pat. Off. (21) Appl. No.: 986,299 0281482 3/1988 European Pat. Off. 035.0246 7/1989 European Pat. Off. 22 Filed: Dec. 7, 1992 2-212436 8/1990 Japan. Related U.S. Application Data OTHER PUBLICATIONS 63) continuation of ser. No. 777,170, oct. 16, 1991, aban- Chemical Abstracts, vol. 114/No. 6 (Feb. 11, 1991); doned. Columbus, Ohio; Abstract No. 49615R. 30 Foreign Application Priority Data Primary Ent, S. Sir Mueller & Oct. 16, 1990 (JP) Japan .................................. 2-278037 story Agent, or Firm-Wegner, Cantor, Mueller Aug. 28, 1991 JP Japan .................................. 3.217045 51 Int, Cl. ......................... A61K 9/22; A61K 9/52; ' ABSTRACT A61K 31/74 A polymer for a prolonged release preparation which 52 U.S. Cl. ................................. 424/426; 424/78.08; comprises 424/78.37; 424/434; 424/457; 424/468; (A) a polylactic acid and 424/486; 424/497; 525/450, 514/2 (B) a copolymer of glycolic acid and a hydroxycar 58) Field of Search .................. 424/426, 78.08, 78.37, boxylic acid of general formula 424/434, 457, 468, 486, 497; 525/450; 514/2 (56) References Cited R U.S.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • LIGAND FORMULA INDEX CH5N 1 C3hlln3 68 CH603NP Z97 C3hll
    LIGAND FORMULA INDEX CH5N 1 C3HllN3 68 CH 0 NP Z97 6 3 C3Hll °3Nl 304 C3HIZ0gNP3 319 C H O N 164 Z 3 Z 3 C3HIZ0l0NP3 3Z0 CZH4OZN4 164 C H N 335 Z 5 C4H304N3 343 C H 0 N 347 Z 5 Z Z C4H4NZ 263,263,264 C H 0N Z6 Z 6 Z C4H402N2 34Z C H O N Z 6 Z 4 56 C4H403NZ 34Z C H N Z,72 2 7 C4H5ON Z 264 C H NS 3Z Z 7 C4H6NZ 146,148,149,349 C H 0N 15 Z 7 C4H6ON Z 15Z,15Z C H 0 NS 10 Z 7 3 C4H7N3 155 C H 0 NS 331 Z 7 4 C4H9N 7,73 C H N 36 2 8 Z C4HgN3 S2 348 C H 0 NP Z 8 3 Z98,246 C4HgON 81 C H 0 NP 3Z9 Z 8 4 C4HgON 2 348 C4HgOZN Z4,333,333 C H N 144,349 3 4 Z C4HgOZNS 33 C3H7N 6,331,335 C4H9OZN3 28,348 C H 0 N 23 3 7 2 C4Hg03 N 18 C3H80N 79 C4H904N2 77 Z7,3L,7 C3H80N2 C4H10NZ 91 3,331 C3HgN C4Hl00ZNZ 59 33,%7 C3H9NS C4H1006NP 346 347 C3HgN3 S C4HllN 3,5,7Z,331,331 C H ON 3 g 16,16,21 C4Hll NS 348 C H O N 347 3 g Z C4HllON 17,79,115,33Z,33Z,347 10 C3Hg03 NS C4HllONS 35 C H N 39,51,8Z 3 10 Z C4HllOZN 19,80 C H ON 57 3 10 Z C4Hl103N ZO 298,300,301 C3HIOO3 NP C4Hll03NS 11 393 394 LIGAND FORMULA INDEX C4H1ZN2 40,40,41,42,S2,S4,83,88,lZ0 CsHn 02N3 29,29 C4H12N2S 6S C5H12NZ 91,92,124 C4H12NZS2 66 CSH120NZ 14 C4H1ZON 2 S8,9S CSH1202NZ 334 C4H1Z03NP Z99,346 CSH13N 4,331,33S C4H13N3 69,101 CSH130N 17,337 C4H1306NPZ 318 CSH130ZN 117,336,347 C4H1404Nl2 Z93 CSH1303NS 11 C4H1406NZPZ 30S CSH14NZ S3,SS,84,84,92,337 CSH140N Z 96,97,348,348 CSH3N4Cl 344 CSH1403NP 317,346 CSH4NBr 340,340 CSH140SNP 317 CSH4NCI 340,340 CSHlSN3 103,103 CSH4N4 344 CSH16 N4 71 CSH4N4S 344 CSH1709Nl3 346 CSH40N4 34S CSH40ZN4 34S C6H4N2 177,177 CSHSN 16S C6H4ON4 3S3 CSHSNS 276 C6H402N4 3S3 CSHSNSS
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • Alfadolone Acetate (BANM, Rinnm) 362: 1749–57
    1780 General Anaesthetics blood, then to the brain; recovery is a function of the zolam, and other anaesthetics such as etomidate, propofol, ful if the patient’s cooperation is required, as conscious- removal of the anaesthetic from the brain. With inject- or ketamine. Small doses of short-acting opioids, for ex- ness soon returns once the nitrous oxide is stopped. The able anaesthetics their activity is similarly dependent ample alfentanil, fentanyl, or remifentanil, given before or neuroleptic most commonly employed was droperidol and on their ability to penetrate the blood/brain barrier and at induction allow the use of smaller induction doses of it was usually used with fentanyl although other opioids recovery in turn is governed by their redistribution and some drugs used for anaesthesia, and this technique is par- have also been used. These procedures have since evolved ticularly suitable for poor-risk patients. into conscious sedation and monitored anaesthetic care excretion. The potency of inhalational anaesthetics is After induction, muscle relaxation with a rapidly acting techniques employing newer drugs. often expressed in terms of minimum alveolar concen- depolarising neuromuscular blocker such as suxamethoni- Ketamine used alone can produce a state of dissociative trations, known as MAC values. The MAC of an um aids intubation of the patient. Longer acting, compet- anaesthesia similar to that of neuroleptanalgesia in which anaesthetic is the concentration at 1 atmosphere that itive neuromuscular blockers may then be given to allow the patient may appear to be awake but is unconscious. will produce immobility in 50% of subjects exposed to procedures such as abdominal surgery to be carried out un- Marked analgesia and amnesia are produced, but there a noxious stimulus.
    [Show full text]
  • G Genito Urinary System and Sex Hormones
    WHO/EMP/RHT/TSN/2018.2 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Learning clinical pharmacology with the use of INNs and their stems. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.2). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.
    [Show full text]